Profile data is unavailable for this security.
About the company
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
- Revenue in USD (TTM)42.34bn
- Net income in USD13.50bn
- Incorporated1900
- Employees114.00k
- LocationAbbott Laboratories100 Abbott Park Road, Abbot ParkABBOTT PARK 60064-3500United StatesUSA
- Phone+1 (224) 667-6100
- Websitehttps://www.abbott.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Becton Dickinson and Co | 20.87bn | 1.50bn | 50.43bn | 74.00k | 34.08 | 2.00 | 13.04 | 2.42 | 5.16 | 5.16 | 71.96 | 88.07 | 0.3842 | 3.32 | 7.47 | 281,986.50 | 2.76 | 2.55 | 3.20 | 2.92 | 44.68 | 45.30 | 7.18 | 7.29 | 0.6427 | 7.18 | 0.4329 | 76.93 | 4.16 | 3.14 | 15.99 | 10.56 | -5.40 | 4.29 |
| Cencora Inc | 310.23bn | 1.69bn | 57.22bn | 42.00k | 34.26 | 56.48 | 20.35 | 0.1844 | 8.62 | 8.62 | 1,574.00 | 5.23 | 4.59 | 16.40 | 12.70 | 7,386,481.00 | 2.53 | 1.12 | 10.78 | 4.84 | 3.29 | 3.24 | 0.55 | 0.2556 | 0.517 | 17.30 | 0.8694 | 62.15 | 12.12 | 10.36 | -13.53 | 13.02 | 9.45 | 4.98 |
| Medtronic PLC | 33.54bn | 4.66bn | 115.21bn | 95.00k | 24.86 | 2.40 | 15.26 | 3.44 | 3.62 | 3.62 | 26.01 | 37.46 | 0.3692 | 2.17 | 5.31 | 353,021.10 | 5.16 | 4.55 | 5.95 | 5.15 | 65.39 | 66.25 | 13.99 | 13.07 | 1.42 | 11.19 | 0.3714 | 84.20 | 3.62 | 3.01 | 26.82 | -0.2723 | 8.91 | 5.33 |
| Danaher Corp | 23.82bn | 3.77bn | 146.60bn | 61.00k | 39.72 | 2.88 | 23.95 | 6.15 | 5.16 | 5.16 | 32.62 | 71.06 | 0.2931 | 3.70 | 6.92 | 390,491.80 | 4.63 | 5.91 | 5.09 | 6.54 | 59.80 | 59.40 | 15.81 | 19.38 | 1.05 | 15.55 | 0.2447 | 14.68 | -0.0628 | 5.92 | -7.17 | 10.53 | 16.98 | 9.40 |
| Stryker Corp | 23.22bn | 2.86bn | 148.84bn | 53.00k | 52.56 | 7.11 | 37.96 | 6.41 | 7.41 | 7.41 | 60.17 | 54.78 | 0.5437 | 1.62 | 6.25 | 438,075.50 | 6.69 | 6.64 | 8.11 | 7.94 | 64.57 | 63.83 | 12.31 | 13.02 | 0.9985 | -- | 0.445 | 44.01 | 10.23 | 8.71 | -5.43 | 7.52 | 3.07 | 9.27 |
| Boston Scientific Corp | 17.55bn | 2.03bn | 152.68bn | 53.00k | 75.65 | 6.87 | 46.04 | 8.70 | 1.36 | 1.36 | 11.79 | 15.02 | 0.4571 | 2.02 | 7.03 | 331,188.70 | 5.27 | 3.08 | 6.10 | 3.57 | 68.73 | 68.51 | 11.54 | 7.78 | 0.8834 | 9.84 | 0.335 | 0.00 | 17.61 | 9.30 | 18.03 | 25.38 | 5.31 | -- |
| Thermo Fisher Scientific Inc | 42.90bn | 6.52bn | 164.16bn | 125.00k | 25.52 | 3.32 | 17.15 | 3.83 | 17.04 | 17.04 | 112.23 | 130.84 | 0.4374 | 4.86 | 4.47 | 343,184.00 | 6.73 | 7.68 | 7.81 | 9.02 | 41.34 | 44.24 | 15.38 | 16.64 | 1.38 | 24.80 | 0.4086 | 7.09 | 0.0513 | 10.92 | 5.67 | 11.33 | 8.62 | 15.48 |
| Intuitive Surgical Inc | 8.71bn | 2.48bn | 183.53bn | 15.64k | 75.10 | 10.73 | 60.67 | 21.06 | 6.82 | 6.82 | 24.01 | 47.73 | 0.4973 | 2.01 | 7.42 | 557,289.90 | 14.23 | 12.31 | 15.61 | 13.71 | 67.09 | 67.30 | 28.62 | 26.11 | 3.97 | -- | 0.00 | 0.00 | 17.24 | 13.27 | 29.18 | 10.98 | 21.16 | -- |
| Abbott Laboratories | 42.34bn | 13.50bn | 229.69bn | 114.00k | 17.06 | 4.71 | 13.78 | 5.42 | 7.74 | 7.74 | 24.23 | 28.05 | 0.5502 | 2.76 | 6.08 | 371,438.60 | 17.54 | 10.17 | 21.36 | 12.46 | 56.06 | 56.19 | 31.89 | 18.50 | 1.27 | 43.72 | 0.2125 | 44.79 | 4.59 | 5.63 | 134.18 | 30.06 | 6.14 | 11.44 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2025 | 161.83m | 9.33% |
| BlackRock Fund Advisorsas of 31 Mar 2025 | 87.82m | 5.06% |
| SSgA Funds Management, Inc.as of 31 Mar 2025 | 77.66m | 4.48% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2025 | 66.82m | 3.85% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2025 | 50.73m | 2.93% |
| Geode Capital Management LLCas of 31 Mar 2025 | 36.90m | 2.13% |
| Wellington Management Co. LLPas of 31 Mar 2025 | 29.16m | 1.68% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2025 | 28.61m | 1.65% |
| Norges Bank Investment Managementas of 31 Dec 2024 | 20.98m | 1.21% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2025 | 18.63m | 1.07% |
